Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80

Moomoo NewsOct 29 08:31 ET · Ratings

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

GlobeNewswireOct 24 08:00 ET

H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65

Moomoo NewsOct 24 06:31 ET · Ratings

Buy Rating on Jasper Therapeutics Backed by Strategic Clinical Program Expansion and Promising Preliminary Results

TipRanksOct 24 06:29 ET · Ratings

Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55

Moomoo NewsOct 23 11:31 ET · Ratings

Express News | Jasper Therapeutics: Data From Newly Added 360Mg Single-Dose Cohort Is Expected to Be Reported in H1 2025

ReutersOct 23 08:04 ET